NASDAQ$HLVX
HilleVax Inc · Q4 2022 earnings
Q4 2022 earnings · · Investor relations
Briefing
Reported full year financial results and highlighted recent company progress.
HilleVax reported its full year 2022 financial results, highlighting the initiation and execution of the Phase 2b clinical trial NEST-IN1 and the completion of its initial public offering.
- Announced positive immunogenicity results for the NEST-IN1 run-in cohort in Q4 2022.
- The company had cash and cash equivalents totaling $279.4 million as of December 31, 2022.
- Research and development expenses for the fourth quarter 2022 were $17.6 million.
- Net loss for the fourth quarter 2022 was $21.2 million.
Headline financials
Revenue & EPS history
HilleVax · Revenue · Quarterly
$0
Forward guidance
HilleVax expects to complete enrollment of NEST-IN1 clinical trial in 2023 and announce top line safety and clinical efficacy data in the first quarter of 2024.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 6 quarterly earnings reports
-3.3%
Avg return
Earnings day
-2.3%
Avg return
5 days after
-0.9%
Avg return
30 days after
22%
4 / 18 earnings
Positive
+7.9%
Q4 2024
Best reaction
-16.7%
Q2 2023
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q3 2025 | — | — | — | |
| Q2 2025 | +0.5% | +0.5% | +2.0% | |
| Q1 2025 | -1.0% | -5.6% | -6.7% | |
| Q4 2024 | +7.9% | -10.1% | +17.0% | |
| Q3 2024 | -2.6% | +1.6% | +2.6% | |
| Q2 2024 | -0.6% | +5.7% | +8.2% | |
| Q1 2024 | +2.7% | -3.0% | +0.2% | |
| Q4 2023 | -9.0% | -5.4% | -29.5% | |
| Q3 2023 | +1.5% | — | — | |
| Q2 2023 | -16.7% | — | — | |
| Q1 2023 | -1.2% | — | — | |
| Q4 2022 | -12.1% | — | — | |
| Q3 2022 | -8.2% | — | — | |
| Q3 2021 | -8.2% | — | — | |
| Q2 2021 | -6.5% | — | — | |
| Q2 2022 | -6.5% | — | — | |
| Q1 2022 | +0.0% | — | — | |
| Q1 2021 | +0.0% | — | — | |
| Q4 2021 | +0.0% | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro